Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Burkitt Lymphoma

ClinicalTrials.gov lists 969 trials for Burkitt Lymphoma or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 112.

MeSH D002051 Infections Neoplasm C01 C04 C15 C20 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 338 Phase 1/2 Phase 1/2 122 Phase 2 Phase 2 287 Phase 2/3 Phase 2/3 9 Phase 3 Phase 3 67 Phase 4 Phase 4 5 Not applicable Not applicable 70 Observational Observational 68 Phase 1 Phase 1 338 Phase 1/2 Phase 1/2 122 Phase 2 Phase 2 287 Phase 2/3 Phase 2/3 9 Phase 3 Phase 3 67 Phase 4 Phase 4 5 Not applicable Not applicable 70 Observational Observational 68

Trials per phase (log scale)

2 more sections with rows

969 of the 969 trials are tagged with Burkitt Lymphoma itself; the rest are tagged with a narrower condition beneath it.

Get the Burkitt Lymphoma report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Burkitt Lymphoma trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 46

1990: 4 trials (Not applicable 1, Phase 2 3) 1991: 2 trials (Phase 2 2) 1992: 9 trials (Observational 2, Phase 3 1, Phase 2 5, Phase 1 1) 1993: 4 trials (Observational 1, Phase 2 3) 1994: 4 trials (Phase 2 2, Phase 1 2) 1995: 9 trials (Phase 3 2, Phase 2 3, Phase 1/2 1, Phase 1 3) 1996: 14 trials (Observational 3, Phase 2 6, Phase 1 5) 1997: 30 trials (Not applicable 2, Phase 3 6, Phase 2/3 1, Phase 2 9, Phase 1/2 2, Phase 1 10) 1998: 36 trials (Not applicable 1, Phase 4 1, Phase 3 2, Phase 2/3 1, Phase 2 16, Phase 1/2 3, Phase 1 12) 1999: 46 trials (Observational 1, Not applicable 3, Phase 3 6, Phase 2 8, Phase 1/2 5, Phase 1 23) 2000: 46 trials (Observational 1, Not applicable 4, Phase 3 5, Phase 2 18, Phase 1/2 3, Phase 1 15) 2001: 22 trials (Not applicable 3, Phase 3 3, Phase 2 7, Phase 1/2 1, Phase 1 8) 2002: 36 trials (Observational 1, Not applicable 4, Phase 4 1, Phase 3 4, Phase 2 10, Phase 1/2 2, Phase 1 14) 2003: 33 trials (Observational 1, Not applicable 6, Phase 3 2, Phase 2 10, Phase 1/2 6, Phase 1 8) 2004: 44 trials (Observational 1, Not applicable 6, Phase 3 3, Phase 2 15, Phase 1/2 2, Phase 1 17) 2005: 40 trials (Observational 3, Not applicable 4, Phase 3 2, Phase 2 14, Phase 1/2 5, Phase 1 12) 2006: 34 trials (Observational 4, Not applicable 3, Phase 3 3, Phase 2 9, Phase 1/2 3, Phase 1 12) 2007: 38 trials (Other 1, Observational 4, Not applicable 3, Phase 3 4, Phase 2 11, Phase 1/2 3, Phase 1 12) 2008: 33 trials (Observational 8, Not applicable 2, Phase 3 6, Phase 2 7, Phase 1/2 3, Phase 1 7) 2009: 29 trials (Other 1, Observational 6, Not applicable 2, Phase 3 1, Phase 2 6, Phase 1/2 2, Phase 1 11) 2010: 28 trials (Observational 3, Not applicable 4, Phase 2 11, Phase 1/2 2, Phase 1 8) 2011: 22 trials (Not applicable 2, Phase 3 2, Phase 2 10, Phase 1/2 4, Phase 1 4) 2012: 14 trials (Observational 1, Not applicable 1, Phase 3 2, Phase 2 3, Phase 1/2 3, Phase 1 4) 2013: 26 trials (Observational 2, Phase 2 7, Phase 1/2 4, Phase 1 13) 2014: 20 trials (Not applicable 3, Phase 3 2, Phase 2 4, Phase 1/2 3, Phase 1 8) 2015: 15 trials (Not applicable 1, Phase 4 1, Phase 2 6, Phase 1/2 3, Phase 1 4) 2016: 24 trials (Observational 2, Not applicable 2, Phase 4 1, Phase 2/3 1, Phase 2 5, Phase 1/2 4, Phase 1 9) 2017: 30 trials (Observational 1, Phase 3 2, Phase 2 11, Phase 1/2 5, Phase 1 11) 2018: 25 trials (Observational 1, Phase 2 11, Phase 1/2 5, Phase 1 8) 2019: 33 trials (Not applicable 2, Phase 3 3, Phase 2 11, Phase 1/2 4, Phase 1 13) 2020: 22 trials (Observational 3, Phase 2 4, Phase 1/2 2, Phase 1 13) 2021: 27 trials (Observational 4, Phase 3 1, Phase 2 6, Phase 1/2 5, Phase 1 11) 2022: 33 trials (Observational 1, Phase 4 1, Phase 2 11, Phase 1/2 11, Phase 1 9) 2023: 25 trials (Observational 3, Not applicable 1, Phase 3 1, Phase 2 4, Phase 1/2 5, Phase 1 11) 2024: 25 trials (Observational 2, Not applicable 3, Phase 2/3 1, Phase 2 4, Phase 1/2 6, Phase 1 9) 2025: 43 trials (Observational 4, Not applicable 4, Phase 3 1, Phase 2/3 3, Phase 2 8, Phase 1/2 6, Phase 1 17)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 30
2025 43
2024 25
2023 25
2022 33
2021 27
2020 22
2019 33
2018 25
2017 30

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 37 trials starting in 2026 and about 35 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 97 trials still running at the 2026-10-09 snapshot; registered median of 49 months across 626 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Burkitt Lymphoma trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 338
Phase 1/2 122
Phase 2 287
Phase 2/3 9
Phase 3 67
Phase 4 5
Not applicable 70
Observational 68
Expanded access 2
Unknown 1

How many Burkitt Lymphoma trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 26
Recruiting 114
Active, not recruiting 50
Available 1
Completed 508

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Burkitt Lymphoma trials? (3)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 112
Children's Oncology Group 24
National Institutes of Health Clinical Center (CC) 14

Which drugs are being tested for Burkitt Lymphoma? (3)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 212
RITUXIMAB 106
Prednisone 65

Interventions as named in the registry (12)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SQ Fludarabine 114
Etoposid 95
Peripheral blood stem cell transplantation 93
Filgrastime (G-CSF) 89
Cytarabine IT 84

Showing 5 of 12 interventions.

Start your 14-day trial Email me all 12 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Burkitt Lymphoma trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Neutrophil count decreased 1,035 26
Platelet count decreased 863 26
Febrile neutropenia 780 58
White blood cell decreased 694 14
Anemia 490 23

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Burkitt Lymphoma? (110)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial. Blood advances 2025 Yes
Reduced-dose chemotherapy followed by blinatumomab in induction therapy for newly diagnosed B-cell acute lymphoblastic leukemia. Cancer medicine 2024 Yes
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial. Haematologica 2024 Yes
Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR. Molecular therapy : the journal of the American Society of Gene Therapy 2023 Yes
Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant. Frontiers in immunology 2023 Yes

Showing 5 of 110 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (12)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Burkitt lymphoma Point prevalence 1-9 / 1 000 000 United States US Exact
Burkitt lymphoma Point prevalence 1-9 / 1 000 000 United States US Unspecified
Burkitt lymphoma Point prevalence 1-9 / 1 000 000 United States US Exact
Burkitt lymphoma Point prevalence Unknown Worldwide Not stated Exact
Burkitt lymphoma Annual incidence 1-9 / 1 000 000 Europe Not stated Exact

Showing 5 of 12 prevalence observations.

Start your 14-day trial Email me all 12 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Burkitt lymphoma 543 Exact Orphanet Rare Disease Ontology (ORDO)
Burkitt lymphoma 543 Exact Orphadata Science knowledge files, Product 1

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages